FLC | DoD's Joint Trauma System launches COVID-19 registry to inform practice

DoD's Joint Trauma System launches COVID-19 registry to inform practice

June 30, 2020

In the war on COVID-19, the Department of Defense will rely on the future development of vaccines and treatments as weapons in its arsenal. Data sets that inform decisions and improve care serve as a key component toward this effort. The staff of the Joint Trauma System (JTS) at Joint Base San Antonio-Fort Sam Houston, Texas, lead that effort.

“Without data, you’re just another person with an opinion,” said Mary Ann Spott, deputy chief of the JTS.

Spott helped create DoD’s Trauma Registry in 2006 and the recently launched COVID-19 registry, which will track patient information and treatment outcomes to help inform best practices.

“A registry provides high-quality data collected in a standardized and consistent format,” she explained. “It allows you to make decisions that impact care positively. So you can look at what everyone is doing and pick best of breed and promulgate it through the entire system.”

Insights from the trauma registry prompted changes across the DoD in resuscitation and blood transfusions of trauma cases, said Air Force Col. (Dr.) Stacy Shackelford, chief of the JTS. By analyzing data in the trauma registry, researchers found that a blood transfusion received within the first 30 minutes of injury led to increased survival.

“This evolved to all special operations medics being trained in blood transfusions and providing blood to carry in aid bags,” Shackelford said.

In the same way, the COVID-19 registry could provide critical understanding to make performance improvement guidelines. Working with infectious disease experts from Uniformed Services University of Health Sciences in Bethesda, Maryland, the JTS deployed the COVID-19 registry in a matter of months to consolidate data collection across all military hospitals and clinics around the world.

The registry will capture approximately 195 unique data points, including demographics, symptoms, past medical history, lab and radiology tests, contact with known infected patients, treatments, outcomes, and complications. By identifying data points of patients and linking data to specific treatments and outcomes, researchers can draw conclusions and recommendations. Shackelford admits she finds such analysis challenging and complicated. Data must take into account risk factors, which places a burden of responsibility to ensure accurate and meaningful conclusions. Otherwise, she said, you may end up with inaccurate information.

“This registry, which already includes data from 6,510 patients, will support COVID-19 clinical performance improvement and track the epidemiology of the disease,” said Thomas McCaffery, the Assistant Secretary of Defense for Health Affairs, in a recent announcement. “The data will help research and medical teams, both in the DoD and the civilian sector, provide more accurate insight into future advancements in vaccines and treatments.”

While the registry will collect information on potential drug treatments for COVID-19, the first priority will be to study the use of COVID-19 convalescent plasma (CCP) in patients, Shackelford said.

“The registry also will track the outcomes of patients who receive CCP compared to those who do not – all of which will greatly enhance efforts toward therapeutic treatment development,” McCaffery added.

The ability to track patients through the continuum of care represents a unique component of DoD registries. The COVID-19 registry will track patients from the first visit to the achievement of a negative COVID test to the 30-day period after leaving the hospital. As the clinical understanding of COVID-19 continues to evolve, the registry will adapt to include new treatments as outlined by the Centers for Disease Control and Prevention and the Society of Critical Care Medicine, Shackelford added.

Location information in the registry could help identify potential hot spots and lead to the deployment of military medical units and equipment in response to an outbreak, according to Spott. The system will also flag recovered patients who live within 40 miles of a blood collection center to identify potential CCP donors. For those patients who live more than 60 miles away from a blood center, mobile blood units could move out to secure donations, Shackelford said. The registry may also help identify asymptomatic cases.

“One of the important things we are implementing right now is to be able to tie symptom survey results to lab testing,” she added.

In the long term, Spott believes, the COVID-19 registry may help with future viral outbreaks.

“We have a good infrastructure now; we’ve put a lot of thought and effort into this and we could apply it to other pandemics and also other epidemics,” she said.

Shackelford labeled as key having the full capability of data analysis, performance improvement, and clinical practice guidelines to support decision making by leadership at the highest level on down to unit levels.

“The value of the registry is not just data alone. Just collecting data is essentially not going to change anything, but really linking it to performance improvement guidelines,” she said. “One of our overarching goals at JTS is to establish the framework of a trauma system in every combatant command so we can immediately establish performance improvement in times of war …and this pandemic is a war.”